Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

No studies found 2 · 28.6%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 42.9%Moderate 2 · 28.6%High 0 · 0%

CMV disease · solid organ transplant recipients

Maribavir showed no clear difference in CMV disease compared with ganciclovir (low certainty).

1 finding from 1 review

All‐cause death · solid organ transplant recipients

Maribavir showed no clear difference in all‐cause death compared with ganciclovir (low certainty).

1 finding from 1 review

CMV infection · solid organ transplant recipients

Maribavir probably leads to higher CMV infection compared with ganciclovir (moderate certainty).

1 finding from 1 review

Acute rejection · solid organ transplant recipients

Maribavir showed no clear difference in acute rejection compared with ganciclovir (low certainty).

1 finding from 1 review

Graft loss · solid organ transplant recipients

The review found no eligible studies for this question.

1 finding from 1 review

Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Opportunistic infections · solid organ transplant recipients

The review found no eligible studies for this question.

1 finding from 1 review

Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Adverse events · solid organ transplant recipients

Maribavir showed no clear difference in adverse events compared with ganciclovir (moderate certainty).

1 finding from 1 review

Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients 2024 · Cochrane Headline outcomes only
RR 0.99 [0.79, 1.25]
1 study · 303 participants
Moderate